Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia)

Why It Matters

The acquisitions expand CRL’s biologics testing suite and lock in essential NHP resources, driving faster, more cost‑effective drug development while advancing animal‑reduction initiatives.

Key Takeaways

• Acquires PathoQuest remaining 79% for $60 million.
• Adds NGS QC testing to Charles River’s biologics portfolio.
• Supports NAMs to replace animal use in viral safety.
• Purchases K.F. Cambodia assets for $510 million.
• Secures NHP supply chain, targets margin improvement.

Pulse Analysis

Charles River Laboratories is sharpening its competitive edge by completing two strategic acquisitions that address both cutting‑edge technology and supply‑chain resilience. The full purchase of PathoQuest integrates a next‑generation sequencing platform into CRL’s biologics testing workflow, enabling rapid in‑vitro quality‑control assays that meet GMP standards. This aligns with the industry’s shift toward alternative methods (NAMs) that replace animal testing in viral safety, a move that satisfies regulators and responds to growing ethical pressures.

PathoQuest’s NGS solution shortens turnaround times for biopharma clients, delivering high‑resolution data that accelerates batch release and reduces development cycles. By embedding this capability, CRL can offer a more comprehensive suite of services—from early‑stage discovery to late‑stage manufacturing—while positioning itself as a go‑to partner for companies seeking to modernize their quality‑control pipelines. The technology also dovetails with the Alternative Methods Advancement Project (AMAP), reinforcing CRL’s commitment to innovative, animal‑free testing approaches.

The acquisition of K.F. (Cambodia) fortifies CRL’s non‑human primate (NHP) supply chain, a critical component for in‑vivo safety studies required by regulators worldwide. Controlling these assets is expected to generate significant cost synergies, boosting operating margins across the discovery and safety assessment segment. Moreover, securing a reliable NHP source mitigates geopolitical and logistical risks, ensuring uninterrupted support for clients’ preclinical programs. Together, these moves underscore CRL’s strategy to blend traditional in‑vivo expertise with next‑gen in‑vitro technologies, delivering end‑to‑end solutions that enhance efficiency, compliance, and ethical standards in drug development.